Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05377996 · ClinicalTrials.gov registry record · Phase 1
A Study of XMT-1660 in Participants With Solid Tumors
A Phase 1 study of Breast Cancer and Ovarian Cancer, sponsored by Mersana Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 319
- Enrollment target
- 20
- Study locations
NCT05377996: Recruiting Phase 1 study of Breast Cancer and Ovarian Cancer, sponsored by Mersana Therapeutics.
NCT05377996 is a Phase 1 study of Breast Cancer and Ovarian Cancer that is actively recruiting participants, run by Mersana Therapeutics. The registered enrollment target is 319 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (89% lower). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05377996, a Phase 1 study of Breast Cancer and Ovarian Cancer, is actively recruiting participants, sponsored by Mersana Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 319 participants
- Enrollment target
- 20
- Study locations
Study Summary
A Study of XMT-1660 in Solid Tumors
Primary Outcome
Determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of Emi-Le
Conditions Studied
Interventions
- DRUG XMT-1660
Study Locations (20)
California
- UC Irvine Health-Chao Family Comprehensive Cancer Center - Orange
- UCSF Helen Diller Family Comprehensive Cancer Center - San Francisco
- UCLA - Santa Monica
Florida
- Mayo Clinic - Jacksonville - Jacksonville
- Florida Cancer Specialists - Sarasota
- Moffitt Cancer Center - Tampa
New York
- New York University Langone Health - New York
- ICHAN School of Medicine at Mount Sinai - New York
- Memorial Sloan Kettering Cancer Center - New York
Massachusetts
- Beth Israel Deaconess Medical Center - Boston
- Dana-Farber Cancer Institute - Boston
Arizona
- Mayo Clinic Comprehensive Cancer Center - Phoenix
Georgia
- Winship Cancer Institute, Emory University - Atlanta
Illinois
- Northwestern University - Chicago
Michigan
- Henry Ford Health Hospital - Detroit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 319 participants |
| Start Date | 2022-08-15 |
| Est. Completion | 2027-05 |
| Phase | Phase 1 |
What NCT05377996 shows while recruiting
NCT05377996 is an interventional study that assigns participants to a tested intervention. The registered 319 participants enrollment target is mid-sized for trials with a published cap, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (89% lower).
The record links to 7 conditions, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which XMT-1660 is the first listed.
NCT05377996 names 20 study sites across 13 states, led by California, Florida, New York.
Frequently Asked Questions
What is clinical trial NCT05377996 about?
NCT05377996 is a clinical study titled "A Study of XMT-1660 in Participants With Solid Tumors". A Study of XMT-1660 in Solid Tumors
What is the current status of trial NCT05377996?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 319 participants. The study started on 2022-08-15. Estimated completion is 2027-05.
What conditions does trial NCT05377996 study?
This clinical trial studies the following conditions: Breast Cancer, Ovarian Cancer, Endometrial Cancer, Triple Negative Breast Cancer, Fallopian Tube Cancer.
What interventions are being tested in trial NCT05377996?
The interventions under investigation include: XMT-1660 (DRUG).
Who is sponsoring clinical trial NCT05377996?
This trial is sponsored by Mersana Therapeutics, which has 11 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05377996 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05377996's enrollment target sits among peer trials
319 269th of 1224 higher than 956 of 1,224 other Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
VS-6766+Abema+Fulv in Met HR+/HER- BC
RECRUITING · Phase 1
-
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
RECRUITING · Phase 1
-
Focused Ultrasound and Gemcitabine in Breast Cancer
RECRUITING · Phase 1
-
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02763683 · 320 participants
Investigations of Dementia in Parkinson Disease
- NCT03331198 · 320 participants · Phase 1
Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
- NCT03458832 · 320 participants
Clinical Trial Readiness to Solve Barriers to Drug Development in FSHD
- NCT03551951 · 320 participants
Tumor Cell and DNA Detection in the Blood, Urine, and Bone Marrow
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI